ribavirin
molecul
antivir
activ
differ
virus
clinic
practic
made
nich
almost
exclus
treatment
hepat
c
viru
howev
diseas
could
benefit
advantag
suitabl
oral
intraven
inhal
administr
conduct
review
indic
main
drug
agenc
spanish
european
american
possibl
indic
mainli
haemorrhag
fever
coronaviru
palabra
clave
ribavirina
virazol
r
e
u
e
n
la
ribavirina
es
una
con
actividad
antivir
sobr
diferent
viru
ha
encontrado
su
hueco
en
la
de
forma
casi
exclusiva
para
el
tratamiento
del
viru
de
la
hepat
c
pero
existen
otra
enfermedad
que
beneficiars
de
su
empleo
su
disponibilidad
para
por
oral
por
intravenosa
e
inhalada
es
una
beneficiosa
en
est
trabajo
se
realiza
una
de
la
indicacion
en
la
principal
agencia
del
medicamento
europea
americana
como
de
otra
posibl
indicacion
principalment
sobr
fiebr
coronaviru
ribavirin
molecul
synthesis
first
time
also
known
name
virazol
pyrimidin
nucleosid
design
vitro
broadspectrum
agent
first
descript
publish
journal
scienc
action
dna
herp
viru
murin
cytomegaloviru
vaccin
viru
adenoviru
type
rna
virus
rabiesrel
virus
viru
respons
myxoma
parainfluenza
viru
type
influenza
b
rhinoviru
coxsacki
b
polioviru
type
vesicular
stomat
viru
semliki
forest
viru
detail
work
subsequ
activ
viral
diseas
determin
found
place
clinic
practic
almost
exclus
treatment
hepat
c
viru
hcv
paper
review
refer
pubm
databas
decemb
carri
cross
english
keyword
ribavirin
correspond
follow
virus
diseas
adenoviru
hantaviru
syncyti
respiratori
viru
lassa
fever
crimeancongo
haemorrhag
fever
argentinian
haemorrhag
fever
coronaviru
articl
written
english
spanish
review
preferenti
select
metaanalys
diseas
event
exist
phase
ii
iii
iv
clinic
trial
review
final
found
previou
search
review
case
case
seri
elsevi
slu
sociedad
de
enfermedad
infecciosa
right
reserv
publish
perform
case
refer
work
obtain
articl
review
differ
mechan
action
propos
molecul
like
scenario
work
differ
way
differ
virus
first
mechan
suggest
interfer
de
novo
synthesi
guanosin
deriv
particular
guanosin
triphosph
gtp
inosin
monophosph
dehydrogenas
catalys
format
xanthin
monophosph
inosin
monophosph
subsequ
continu
synthesi
pathway
guanosin
deriv
ribavirin
monophosph
capabl
competit
potent
inhibit
enzym
reduc
reserv
nucleotid
nucleosid
half
treat
cell
antivir
activ
parallel
deplet
gtp
reserv
demonstr
studi
yellow
fever
viru
paramyxoviru
respiratori
syncyti
viru
rsv
secondli
immunomodulatori
activ
suggest
indic
ribavirin
may
increas
activ
lymphocyt
particular
th
lymphocyt
hypothesi
base
observ
treatment
ribavirin
patient
infect
hcv
could
reduc
cytolysi
without
modifi
circul
viral
load
therefor
would
exclus
antivir
effect
observ
lenantiom
ribavirin
levovirin
present
direct
antivir
activ
capabl
also
produc
induct
respons
murin
model
support
hypothesi
howev
possibl
recognis
immunomodulatori
effect
vivo
even
mathemat
model
design
conclud
effect
base
direct
antivir
activ
anoth
mechan
propos
direct
inhibit
polymeras
main
intracellular
metabolit
ribavirin
ribavirin
triphosph
rtp
way
could
competit
inhibitor
similar
nitrogen
base
adenosin
triphosph
atp
gtp
effect
observ
studi
conduct
influenza
viru
reoviru
vesicular
stomat
viru
rna
virus
contain
structur
essenti
stabil
rna
synthesis
three
differ
catalyt
process
virus
translat
process
measur
molecul
known
eukaryot
translat
initi
factor
ribavirin
molecul
could
interact
enzym
respons
cap
rna
cap
synthesi
bind
prevent
start
translat
mechan
could
respons
antivir
activ
observ
virus
lassa
fever
sar
lastli
mechan
mutagenesi
propos
given
structur
similar
incorpor
ribavirin
rna
chain
would
possibl
would
produc
mutant
virus
replic
howev
would
alter
origin
chain
replac
gtp
rtp
also
bind
complementari
base
cytidin
thymidin
uracil
efficaci
due
spatial
arrang
flexibl
rotat
carboxamid
group
mutagen
effect
ribavirin
demonstr
studi
polioviru
handfootandmouth
diseas
west
nile
viru
hantaviru
mention
previous
clinic
use
ribavirin
almost
exclus
limit
treatment
hcv
infect
howev
review
perform
indic
main
medicin
agenc
spanish
agenc
medicin
medic
devic
european
medicin
agenc
us
food
drug
administr
fda
less
wellknown
approv
indic
found
drug
virazol
form
vial
respiratori
inhal
found
websit
spanish
agenc
medicin
medic
devic
mention
specif
indic
state
drug
current
market
spain
suppli
problem
use
aerosol
children
sever
lower
respiratori
tract
infect
caus
rsv
treatment
consist
nebulis
h
period
three
seven
day
european
medicin
agenc
websit
two
applic
ribavirin
investig
apart
indic
hcv
also
found
adenoviru
infect
hantaviru
infect
case
decid
withdraw
consider
indic
final
approv
virazol
nebulis
indic
fda
websit
although
condit
specifi
review
clinic
evid
effect
ribavirin
treat
infect
caus
rsv
adenoviru
hantaviru
metaanalysi
carri
cochran
databas
systemat
review
relat
use
ribavirin
lower
respiratori
tract
infect
children
adolesc
two
subsequ
updat
one
withdrawn
latest
review
therefor
one
publish
review
analys
clinic
trial
conclus
reach
ribavirin
effect
reduc
mortal
develop
respiratori
deterior
howev
reduct
hospit
stay
number
day
mechan
ventil
approxim
two
day
case
observ
anoth
differ
aspect
use
ribavirin
transplant
recipi
treatment
respiratori
infect
caus
rsv
shah
chemali
carri
review
literatur
regard
work
perform
adult
transplant
recipi
rsv
infect
publish
evalu
studi
prospect
retrospect
randomis
observ
clinic
trial
main
variabl
mortal
attribut
rsv
diseas
progress
use
ribavirin
form
aerosolis
oral
intraven
appear
work
overal
conclus
use
ribavirin
whether
associ
immunoglobulin
reduc
progress
diseas
lower
respiratori
tract
reduc
mortal
inhal
ribavirin
use
especi
effect
associ
immunoglobulin
although
diffus
consolid
parenchyma
could
reduc
cost
main
drawback
therapi
approxim
per
patient
firstli
must
point
publish
literatur
review
articl
pubm
metaanalys
clinic
trial
scientif
evid
avail
case
seri
isol
case
seven
publish
case
seri
isol
case
account
total
publish
experi
less
case
tabl
observ
heterogen
regard
viru
treat
serotyp
characterist
patient
age
gender
risk
factor
syndrom
produc
pneumonia
cystiti
digest
diseas
focaldissemin
diseas
diseas
progress
time
combin
drug
etc
therefor
conclus
obtain
reason
use
approv
date
regard
use
ribavirin
diseas
caus
hantaviru
metaanalysi
publish
more
et
al
worthi
indepth
review
systemat
review
studi
identifi
appli
exclus
criteria
seven
studi
analys
account
total
patient
two
group
haemorrhag
fever
renal
syndrom
hantaviru
pulmonari
syndrom
addit
two
subgroup
studi
conduct
anim
human
distinguish
overal
mortal
hantaviru
pulmonari
syndrom
group
randomis
studi
three
prospect
cohort
identifi
anim
studi
reduct
mortal
observ
treatment
group
versu
placebo
studi
human
mortal
rate
group
haemorrhag
fever
renal
syndrom
group
three
studi
includ
reduct
mortal
observ
ribavirin
use
compar
placebo
versu
mortal
rel
risk
rr
anim
human
subgroup
exist
data
metaanalysi
could
suggest
old
world
hantaviru
infect
haemorrhag
fever
renal
syndrom
could
benefit
use
ribavirin
wherea
would
use
hantaviru
pulmonari
syndrom
author
state
abl
consid
time
diagnosi
administr
ribavirin
hantaviru
pulmonari
syndrom
mortal
rate
may
indic
rapid
progress
diseas
haemorrhag
fever
renal
syndrom
mortal
rate
would
key
factor
indic
greater
need
start
therapi
earli
stage
anoth
bia
may
restrict
work
select
accord
languag
work
publish
english
spanish
portugues
select
given
china
case
hantaviru
haemorrhag
fever
period
total
case
haemorrhag
fever
renal
syndrom
report
clear
tendenc
reduc
incid
possibl
priori
inform
publish
chines
elimin
would
modifi
result
obtain
lastli
must
taken
account
list
hantavirus
extens
includ
hantaan
seoul
puumala
dobrava
virus
haemorrhag
fever
renal
syndrom
sin
nombr
and
virus
hantaviru
pulmonari
syndrom
heterogen
virus
syndrom
may
determin
result
may
indic
recent
studi
conduct
evalu
efficaci
safeti
ribavirin
treatment
haemorrhag
fever
renal
syndrom
caus
puumala
viru
benefit
use
ribavirin
open
randomis
studi
patient
receiv
standard
support
therapi
therapi
addit
intraven
ribavirin
studi
abl
demonstr
efficaci
clinic
aspect
viral
kinet
treatment
import
side
effect
mainli
anaemia
hyperbilirubinaemia
sinu
bradycardia
skin
rash
review
perform
treatment
lassa
fever
ribavirin
public
obtain
howev
clinic
trial
metaanalys
evalu
one
refer
relat
effect
treatment
found
studi
conduct
sierra
leon
ministri
health
collabor
center
diseas
control
prevent
also
comorbid
splenectomi
pancreatectomi
mycobacterium
aviumintracellular
infect
c
death
due
colon
adenocarcinoma
case
diseas
due
merscov
treat
interferon
ribavirin
regimen
mg
load
dose
h
day
h
day
regimen
b
load
dose
mg
mg
subsequ
h
dose
lopinavirritonavir
h
administ
oral
regimen
c
load
dose
mg
h
oral
cdc
start
administr
convalesc
plasma
oral
ribavirin
intraven
ribavirin
evalu
studi
rather
complex
howev
despit
fact
conclud
treatment
intraven
oral
ribavirin
recommend
time
diseas
effect
first
six
day
diseas
initi
phase
casecontrol
studi
clinic
diagnost
aspect
lassa
fever
untreat
patient
design
clinic
laboratori
variabl
collect
analys
subsequ
variabl
collect
randomis
trial
conduct
patient
oral
ribavirin
plasma
pregnant
women
includ
without
randomis
latter
group
without
know
time
result
analysi
variabl
collect
case
treatment
start
first
h
subsequ
elev
transaminas
viraemia
greater
copiesml
identifi
poor
prognosi
variabl
later
stage
variabl
indic
poor
prognosi
determin
phase
ii
studi
develop
select
patient
one
poor
prognosi
variabl
elev
transaminas
upon
diagnosi
viraemia
avail
two
group
patient
patient
intraven
ribavirin
group
intraven
ribavirin
plu
plasma
group
randomis
pregnant
women
receiv
two
plasma
unit
overal
treatment
ribavirin
reduc
mortal
includ
analysi
patient
includ
phase
studi
phase
ii
studi
patient
viraemia
copiesml
treat
ribavirin
mortal
lower
receiv
treatment
mortal
intraven
ribavirin
versu
without
therapi
p
mortal
oral
ribavirin
versu
without
therapi
p
occur
viraemia
copiesml
mortal
intraven
ribavirin
versu
without
therapi
p
mortal
oral
ribavirin
versu
without
therapi
p
second
studi
conduct
fisherhoch
et
al
appear
pubm
clinic
trial
regard
use
ribavirin
lassa
fever
although
true
refer
use
clinic
trial
describ
onset
advers
effect
associ
recoveri
shiveringchil
seem
relat
speed
administr
drug
min
side
effect
disappear
correct
speed
infus
studi
conduct
evalu
ribavirin
postexposur
prophylaxi
provid
conclus
result
crimeancongo
haemorrhag
fever
one
randomis
clinic
trial
evalu
use
ribavirin
crimeancongo
haemorrhag
fever
conduct
patient
baselin
form
differ
gender
age
incub
period
around
five
day
clinic
analyt
characterist
administr
ribavirin
done
confirm
diagnosi
mean
time
administr
around
four
day
differ
found
term
mortal
analyt
recoveri
length
hospit
stay
subsequ
two
metaanalys
evalu
use
ribavirin
crimeancongo
haemorrhag
fever
first
review
work
conclus
author
draw
ribavirin
clinic
trial
superior
use
ribavirin
joint
evalu
result
mortal
reduc
rr
ci
particip
found
differ
durat
hospit
admiss
second
metaanalysi
also
includ
randomis
clinic
trial
seven
work
observ
control
group
introduc
benefit
ribavirin
aggreg
data
found
either
metaanalys
underlin
risk
bia
work
whether
select
extern
valid
attrit
bia
ribavirin
manag
demonstr
use
reduct
mortal
due
junin
viru
argentin
haemorrhag
fever
two
small
clinic
trial
nevertheless
first
studi
block
viral
replic
delay
time
death
observ
compar
histor
control
clearanc
viraemia
even
obtain
patient
die
phase
diseas
viru
detect
case
given
treatment
proven
effect
administ
first
seven
day
diseas
convalesc
serum
studi
use
ribavirin
conduct
advanc
stage
diseas
would
justifi
poor
outcom
probabl
possibl
conduct
new
studi
regard
sinc
also
vaccin
proven
effect
reduc
incid
diseas
practic
report
case
machupo
viru
treat
ribavirin
bolivian
haemorrhag
fever
two
isol
case
intraven
ribavirin
administ
recov
appli
case
sabia
viru
one
case
sabia
viru
treat
intraven
ribavirin
manag
cure
patient
one
retrospect
studi
conduct
patient
coronaviru
compar
combin
interferon
ribavirin
versu
placebo
observ
improv
surviv
vs
day
vs
favour
combin
tabl
case
seri
diseas
due
merscov
treat
ribavirin
ifn
drug
although
differ
day
statist
signific
probabl
due
small
sampl
size
mean
treatment
initi
time
ribavirin
three
day
addit
isol
case
case
seri
reflect
variabl
degre
therapeut
success
tabl
report
new
applic
ribavirin
current
investig
four
studi
investig
use
influenza
three
arboviru
three
hepat
b
three
hantaviru
two
paramyxoviru
two
coxsacki
viru
one
coronaviru
regist
ribavirin
broadspectrum
antivir
current
look
new
role
treatment
variou
infect
avail
administr
via
oral
intraven
inhal
rout
benefici
characterist
evid
benefit
rsv
infect
lassa
fever
use
propos
certain
situat
diseas
due
hantaviru
crimeancongo
haemorrhag
fever
coronaviru
middl
east
respiratori
syndrom
coronaviru
merscov
avail
ribavirin
oral
formul
current
exist
spain
inhal
intraven
form
must
request
spanish
agenc
medicin
medic
devic
